摘要
目的:探讨左卡尼汀在尿毒症血液透析治疗中的安全性分析。方法:将2018年6月—2020年6月在该院治疗的200例尿毒症患者均分为两组。对照组(n=100)采用血液透析治疗,观察组(n=100)在对照组的基础上联合左卡尼汀治疗,观察并分析两组的治疗成果。结果:观察组相较于对照组临床疗效方面更优,差异有统计学意义(χ^(2)=18.882,P <0.05)。观察组与对照组不良反应方面相近,差异无统计学意义(χ^(2)=0.421,P=0.516)。观察组美国国立卫生研究院卒中量表(national institute of health stroke scale,NIHSS)和日常生活能力评分量表(activities of daily living,ADL)评分相较于对照组更高,差异有统计学意义(t=14.776、5.858,P<0.05)。治疗后观察组分化抗原CD4(cluster of differentiation 4+,CD4+)、分化抗原CD4/分化抗原CD8(cluster of differentiation 4+/cluster of differentiation 8+,CD4+/CD8+)相较于对照组更高,差异有统计学意义(t=25.927、3.074,P<0.05)。观察组血液指标水平方面相较于对照组更高,差异有统计学意义(t=11.876、13.690、4.457、10.401,P<0.05)。观察组贫血症状改善时间、白蛋白高于30 g/L的时间、红细胞比容增加10%以上的时间相较于对照组更短,差异有统计学意义(t=19.507、8.554、23.904,P <0.05)。观察组转铁蛋白、总蛋白和白蛋白水平方面相较于对照组差异较大(P <0.05)。结论:采用血液透析联合左卡尼汀治疗尿毒症患者,可以改善患者的生活质量,疗效显著,安全性高,具有应用意义。
Objective: To explore the safety analysis of L-carnitine in the treatment of uremic hemodialysis. Methods: From June 2018 to June 2020, the 200 patients with uremia treated in the hospital were divided into two groups. The control group(n = 100) was treated with hemodialysis, and the observation group(n = 100) was treated with L-carnitine on the basis of the control group. The treatment results of the two groups were observed and analyzed. Results: The observation group was better than the control group in terms of clinical efficacy, with a statistically significant difference(χ^(2)= 18.882, P < 0.05). The observation group and the control group were similar in terms of adverse reactions, and the difference was not statistically significant(χ^(2)= 0.421, P = 0.516). The NIHSS and ADL scores of the observation group compared with the control group were higher, the difference was statistically significant(t =14.776、5.858, P<0.05). After treatment, cluster of differentiation 4+(CD4+), cluster of differentiation 4+/cluster of differentiation 8+(CD4+/CD8+) in the observation group compared with the control group were higher, with a statistically significant difference(t =25.927、3.074, P < 0.05). The observation group’s hemoglobin, hematocrit, serum total protein, and serum protein index levels were higher than those of the control group, and the difference was statistically significant(t =11.876、13.690、4.457、10.401, P<0.05). The time to improve anemia symptoms, the time for albumin to be higher than 30 g/L, and the time for hematocrit to increase by more than 10% in the observation group were shorter than those in the control group, and the difference was statistically significant(t =19.507、8.554、23.904, P<0.05). The transferrin, total protein and albumin levels of the observation group compared with the control group were larger, the difference was statistically significant(P<0.05). Conclusion: For patients with uremia, hemodialysis combined with L-carnitine can improve the quality of life of patients, with significant curative effect, high safety, and application significance.
作者
徐亮
徐延国
XU Liang;XU Yanguo(Shenyang Xiaojing hemodialysis Co.,Ltd.hemodialysis room,Liaoning Shenyang 110000;Department of Nephrology,people's Hospital of Shenyang Economic and Technological Development Zone,Liaoning Shenyang 110000)
出处
《中国药物滥用防治杂志》
CAS
2021年第3期322-326,共5页
Chinese Journal of Drug Abuse Prevention and Treatment
作者简介
徐亮(1982.03—),女,汉族,吉林辽源人,本科,主治医师,主要研究方向:肾内科终末期肾病血液透析;通信作者:徐延国(1964.08—),男,汉族,吉林辽源人,本科,副主任医师,主要研究方向:肾内科血液透析。邮箱:xuliangme@163.com。
